Molecular pathology of chondroid neoplasms: Part 2, malignant lesions

Skeletal Radiology

Volumn 35, Issue 12, 2006, Pages 887-894

  Bell, W C ^a   Klein, M J ^a   Pitt, M J ^b   Siegal, G P ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Chondrosarcoma; Cytogenetics; Moleculargenetics

Indexed keywords

CYCLIN DEPENDENT KINASE 4; HELIX LOOP HELIX PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 3; MYC PROTEIN; PARATHYROID HORMONE RELATED PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN BCL 2; PROTEIN P16; RETINOBLASTOMA PROTEIN; SCATTER FACTOR RECEPTOR; TATA BINDING PROTEIN; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR SOX9; TUMOR SUPPRESSOR PROTEIN;

BONE RADIOGRAPHY; CANCER CLASSIFICATION; CANCER GRADING; CHONDROSARCOMA; CHROMOSOME 10P; CHROMOSOME 10Q; CHROMOSOME 11P; CHROMOSOME 11Q; CHROMOSOME 12Q; CHROMOSOME 13Q; CHROMOSOME 14Q; CHROMOSOME 18P; CHROMOSOME 18Q; CHROMOSOME 19; CHROMOSOME 1P; CHROMOSOME 20P; CHROMOSOME 21Q; CHROMOSOME 22Q; CHROMOSOME 5Q; CHROMOSOME 6Q; CHROMOSOME 7P; CHROMOSOME 9P; CHROMOSOME DELETION; CLINICAL FEATURE; CYTOGENETICS; DISEASE ASSOCIATION; GENETIC ANALYSIS; HUMAN; METASTASIS POTENTIAL; MOLECULAR GENETICS; PRIORITY JOURNAL; REVIEW;

BONE NEOPLASMS; CHONDROSARCOMA; HUMANS;

EID: 33750697942     PISSN: 03642348     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00256-006-0217-y     Document Type: Review

References (63)

1. Fechner RE, Mills SE. Cartilaginous Lesions pp 79-128 in: Atlas of tumor pathology, tumors of the bones and joints. Armed Forces Institute of Pathology, 1993.
2. Terek RM. Recent advances in the basic science of chondrosarcoma. Orthop Clin North Am 2006;37:9-14.
3. Orndal C, Mandahl N, Rydholm A, Willen H, Brosjo O, Mitelman F. Chromosome aberrations and cytogenetic intratumor heterogeneity in chondrosarcomas. J Cancer Res Clin Oncol 1993;120(1-2):51-6.
4. Tallini G, Dorfman H, Brys P, Dal Cin P, De Wever I, Fletcher CD, et al. Correlation between clinicopathological features and karyotype in 100 cartilaginous and chordoid tumours. A report from the Chromosomes and Morphology (CHAMP) Collaborative Study Group. J Pathol 2002;196(2):194-203.
5. Swarts SJ, Neff JR, Nelson M, Johansson S, Bridge JA. Chromosomal abnormalities in low grade chondrosarcoma and a review of the literature. Cancer Genet Cytogenet 1997;98(2):126-30.
6. Gunawan B, Weber M, Bergmann F, Wildberger J, Niethard FU, Fuzesi L. Clonal chromosome abnormalities in enchondromas and chondrosarcomas. Cancer Genet Cytogenet 2000;120(2):127-30.
7. Bovee JV, Sciot R, Cin PD, Debiec-Rychter M, van Zelderen-Bhola SL, Cornelisse CJ, et al. Chromosome 9 alterations and trisomy 22 in central chondrosarcoma: A cytogenetic and DNA flow cytometric analysis of chondrosarcoma subtypes. Diagn Mol Pathol 2001;10(4):228-35.
8. Ozaki T, Wai D, Schafer KL, Lindner N, Bocker W, Winkelmann W, et al. Comparative genomic hybridization in cartilaginous tumors. Anticancer Res 2004;24:1721-5.
9. Mandahl N, Gustafson P, Mertens F, Akerman M, Baldetorp B, Gisselsson D, et al. Cytogenetic aberrations and their prognostic impact in chondrosarcoma. Genes, Chromosomes Cancer 2002;33(2):188-200.
10. Sjogren H, Orndal C, Tingby O, Meis-Kindblom JM, Kindblom LG, Stenman G. Cytogenetic and spectral karyotype analyses of benign and malignant cartilage tumours. Int J Oncolfs 2004;24:1385-91.
11. Wrba F, Gullick WJ, Pertl H, Amann F, Salzer-Kuntschik M. Immunohistochemical detection of the c-erbB-2 proto-oncogene product in normal, benign and malignant cartilage tissues. Histopathology 15:71-6.
12. Castresana JS, Barrios C, Gomez L, Kreicbergs A. Amplification of the c-myc proto-oncogene in human chondrosarcoma. Diagn Mol Pathol 1992;1:235-8.
13. Naka T, Iwamoto Y, Shinohara N, Ushijima M, Chuman H, Tsuneyoshi M. Expression of c-met proto-oncogene product (c-MET) in benign and malignant bone tumors. Mod Path 1997;10:832-8.
14. Weisstein JS, Majeska RJ, Klein MJ, Einhorn TA. Detection of c-fos expression in benign and malignant musculoskeletal lesions. J Orthop Res 2001;19:339-45.
15. Franchi A, Calzolari A, Zampi G. Immunohistochemical detection of c-fos and c-jun expression in osseous an cartilaginous tumours of the skeleton. Virchows Archives 1998;432:515-9.
16. Pompetti F, Rizzo P, Simon RM, Freidlin B, Mew DJ, Pass HI, et al. Oncogene alterations in primary, recurrent, and metastatic human bone tumors. J Cell Biochem 1996;63:37-50.
17. Morrison C, Radmacher M, Mohammed N, Suster D, Auer H, Jones S, et al. MYC amplification and polysomy 8 in chondrosarcoma: Array comparative genomic hybridization, fluorescent in situ hybridization, and association with outcome. J Clin Oncol 2005;23:9369-76.
18. Wadayama B, Toguchida J, Yamaguchi T, Sasaki MS, Yamamuro T. p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas. Br J Cancer 1993;68:1134-9.
19. Simms WW, Ordonez NG, Johnston D, Ayala AG, Czerniak B. p53 expression in dedifferentiated chondrosarcoma. Cancer 1995;76:223-7.
20. Grote HJ, Schneider-Stock R, Neumann W, Roessner A. Mutation of p53 with loss of heterozygosity in the osteosarcomatous component of a dedifferentiated chondrosarcoma. Virchows Archives 2000;436:494-7.
21. Oshiro Y, Chaturvedi V, Hayden D, Nazeer T, Johnson M, Johnston DA, et al. Altered p53 is associated with aggressive behavior of chondrosarcoma: A long term follow-up study. Cancer 1998;83:2324-34.
22. Terek RM, Healey JH, Garin-Chesa P, Mak S, Huvos A, Alvino AP. p53 mutations in chondrosarcoma. Diagn Mol Pathol 1998;7:51-6.
23. Raskind WH, Conrad EU, Matsushita M. Frequent loss of heterozygosity for markers on chromosome arm 10q in chondrosarcomas. Genes, Chromosomes Cancer 1996;16:138-43.
24. Asp J, Inerot S, Block JA, Lindahl A. Alterations in the regulatory pathway involving p16, pRb, and cdk4 in human chondrosarcoma. J Orthop Res 2001;19:149-54.
25. van Beerendonk HM, Rozeman LB, Taminiau AH, Sciot R, Bovee JV, Cleton-Jansen AM, et al. Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression. J Pathol 2004;202:359-66.
26. Bovee JV, van den Broek LJ, Cleton-Jansen AM, Hogendoorn PC. Up-regulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcomas and is a late event in central chondrosarcoma. Lab Invest 2000;80:1925-34.
27. Nishida K, Furumatsu T, Takada I, Kawai A, Yoshida A, Kunisada T, et al. Inhibition of human chondrosarcoma cell growth via apoptosis by peroxisome proliferator-activated receptor-gamma. Br J Cancer 2002;86:1303-9.
28. Miyaji T, Nakase T, Onuma E, Sato K, Myoui A, Tomita T, et al. Monoclonal antibody to parathyroid horomone-related protein induces differentiation and apoptosis of chondrosarcoma cells. Cancer Lett 2003;199:147-55.
29. Papachristou DJ, Papachristou GJ, Papaefthimiou OA, Agnantis NJ, Basdra EK, Papavassiliou AG. The MAPK-AP-1/-Runx2 signalling axes are implicated in chondrosarcoma pathobiology either independently or via up-regulation of VEGF. Histopathology 2005;47:565-74.
30. Meis-Kindblom JM, Bergh P, Gunterberg B, Kindblom LG. Extraskeletal myxoid chondrosarcoma: A reappraisal of its morphologic spectrum and prognostic factors based on 117 cases. Am J Surg Pathol 1999;23:636-50.
31. Turc-Carel C, Dal Cin P, Rao U, Darakousis C, Sandberg AA. Recurrent breakpoints at 9q13 and 22q12.2 in extraskeletal myxoid chondrosarcoma. Cancer Genet Cytogenet 1988;30:145-50.
32. Orndal C, Carlen B, Akerman M, Willen H, Mandahl N, Heim S, et al. Chromosomal abnormality t(9;22)(q22;q12) in an extraskeletal myxoid chondrosarcoma characterized by fine needle aspiration cytology, electron microscopy, immunohistochemistry and DNA flow cytometry. Cytopathol 1991;2:261-70.
33. Hirabayashi Y, Ishida T, Yoshida MA, Kojima T, Ebihara Y, Machinami R, et al. Translocation (9;22)(q22;q12). A recurrent chromosome abnormality in extraskeletal myxoid chondrosarcoma. Cancer Genet Cytogenet 1995;8:33-7.
34. Stenman G, Andersson H, Mandahl N, Meis-Kindblom JM, Kindblom LG. Translocation t(9;22)(q22;q12) is a primary cytogenetic abnormality in extraskeletal myxoid chondrosarcoma. Int J Cancer 1995;62:398-402.
35. Sciot R, Dal Cin P, Gletcher C, Samson I, Smith M, De Vos R, et al. t(9;22)(q22-31;q11-12) is a consistent marker of extraskeletal myxoid chondrosarcoma: Evaluation of three cases. Mod Path 1995;8:765-8.
36. Labelle Y, Zucman J, Stenman G, Kindblom LG, Knight J, Turc-Carel C, et al. Oncogenic conversion of a novel orphan nuclear receptor by chromosome translocation. Hum Mol Genet 1995;4:2219-26.
37. Kleinfinger P, Labelle Y, Melot T, Thomas G, Delattre O, Aurias A. Localization of TEC to 9q22.3-q31 by fluorescence in situ hybridization. Ann génét 1996;39:233-5.
38. Brody RI, Ueda T, Hamelin A, Jhanwar SC, Bridge JA, Healey JH, et al. Molecular analysis of the fusion of EWS to an orphan nuclear receptor gene in extraskeletal myxoid chondrosarcoma. American J Pathol 1997;150:1049-58.
39. Panagopoulos I, Mertens F, Isaksson M, Domanski HA, et al. Molecular genetic characterization of the EWS/CHN and RBP56/CHN fusion genes in extraskeletal myxoid chondrosarcoma. Genes, Chromosomes Cancer 2002;35:340-52.
40. Labelle Y, Bussieres J, Courjal F, Goldring MB. The EWS/TEC fusion protein encoded by the t(9;22) chromosomal translocation in human chondrosarcomas is a highly potent transcriptional activator. Oncogene 1999;18:3303-8.
41. Maltais A, Filion C, Labelle Y. The AF2 domain of the orphan nuclear receptor TEC is essential for the transcriptional activity of the oncogenic fusion protein EWS/TEC. Cancer Lett 2002;183:87-94.
42. Ohkura N, Yaguchi H, Tsukada T, Yamaguchi K. The EWS/NOR1 fusion gene product gains a novel activity affection pre-mRNA splicing. J Biol Chem 2002;277:535-43.
43. Sjogren H, Meis-Kindblom J, Kindblom LG, Aman P, Stenman G. Fusion of the EWS-related gene TAF2N to TEC in extraskeletal myxoid chondrosarcoma. Cancer Res 1999;59:5064-7.
44. Bjerkenhagen B, Dietrich C, Reed W, Micci F, Saeter G, Berner A, et al. Extraskeletal myxoid chondrosarcoma: Multimodal diagnosis and identification of a new cytogenetic subgroup characterized by t(9;17)(q22;q11). Virchows Arch 1999;435:524-30.
45. Attwooll C, Tariq M, Harris M, Coyne JD, Telford N, Varley JM. Identification of a novel fusion gene involving hTAFII68 and CHN from a t(9;17)(q22q11.2) translocation in an extraskeletal myxoid chondrosarcoma. Oncogene 1999;18:7599-601.
46. Sjogren H, Wedell B, Meis-Kindblom JM, Kindblom LG, Stenman G, Kindblom JM. Fusion of the NH2-terminal domain of the basic helix-loop-helix protein TCF12 to TEC in extraskeletal myxoid chondrosarcoma with translocation t(9;15)(q22;q21). Cancer Res 2000;60:6832-5.
47. Sandberg AA. Genetics of chondrosarcoma and related tumors. Curr Opin Oncol 2004;16:342-54.
48. Sjogren H, Meis-Kindblom JM, Orndal C, Bergh P, Ptaszynski K, Aman P, et al. Studies on the molecular pathogenesis of extraskeletal myxoid chondrosarcoma-cytogenetic, molecular genetic, and cDNA microarray analysis. Am J Pathol 2003;162:781-92.
49. Laflamme C, Filion C, Bridge JA, Ladanyi M, Goldring MB, Labelle Y. The homeotic protein Six3 is a coactivator of the nuclear receptor NOR-1 and a corepressor of the fusion protein EWS/NOR-1 in human extraskeletal myxoid chondrosarcoma. Cancer Res 2003;63:449-54.
50. Kleist B, Poetsch M, Lang C, Bankau A, Lorenz G, Suess-Fridrich K, et al. Clear cell chondrosarcoma of the larynz: A case report of a rare histologic variant in an uncommon location. Am J Surg Pathol 2002;26:386-92.
51. Sainati L, Scapinello A, Montaldi A, Bolcato S, Ninfo V, Carli M, et al. A mesenchymal chondrosarcoma of a child with the reciprocal translocation (11;22)(q24;q12). Cancer Genet Cytogenet 1993;71:144-6.
52. Dobin SM, Donner LR, Speights VO. Mesenchymal chondrosarcoma. A cytogenetic, immunohistochemical and ultrastructural study. Cancer Genet Cytogenet 1995;83:56-60.
53. Szymanska J, Tarkkanen M, Wiklund T, Virolainen M, Blomqvist C, Asko-Seljavaara S, et al. Cytogenetic study of extraskeletal mesenchymal chondrosarcoma. A case report. Cancer Genet Cytogenet 1996;86:170-3.
54. Naumann S, Krallman PA, Unni KK, Fidler ME, Neff JR, Bridge JA. Translocation der(13;21)(q10;q10) in skeletal and extraskeletal mesenchymal chondrosarcoma. Mod Path 2002;15:572-6.
55. Park YK, Park HR, Chi SG, Kim CJ, Sohn KR, Koh JS, et al. Overexpression of p53 and rare genetic mutation in mesenchymal chondrosarcoma. Oncol Rep 2000;7:1041-7.
56. Wehrli BM, Huang W, De Crombrugghe B, Ayala AG, Czerniak B. Sox9, a master regulator of chondrogenesis, distinguishes mesenchymal chondrosarcoma from other small blue round cell tumors. Human Pathol 2003;34:263-9.
57. Bruns J, Fiedler W, Werner M, Delling G. Dedifferentiated chondrosarcoma-a fatal disease. J Cancer Res Clin Oncol 2005;131(6):333-9.
58. Dickey ID, Rose PS, et al. Dedifferentiated chondrosarcoma: The role of chemotherapy with updated outcomes. J Bone Joint Surg Am 2004;86-A(11):2412-8.
59. Littrell LA, Wenger DE, et al. Radiographic, CT, and MR imaging features of dedifferentiated chondrosarcomas: A retrospective review of 174 de novo cases. Radiographics 2004;24(5):1397-409.
60. Rinaggio J, Duffey D, McGuff HS. Dedifferentiated chondrosarcoma of the larynx. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;97(3):369-75.
61. MacSweeney F, Darby A, Saifuddin A. Dedifferentiated chondrosarcoma of the appendicular skeleton: MRI-pathologic correlation. Skeletal Radiol 2003;32(12):671-8.
62. Casorzo L, Chiecchio L, Pisacane A, Fumero S, Canavese F, Torchio B, et al. Cytogenetic findings in a case of dedifferentiated chondrosarcoma. Cancer Genet Cytogenet 2003;144:61-4.
63. Bovee JV, Cleton-Jansen AM, Rosenberg C, Taminiau AH, Cornelisse CJ, Hogendoorn PC. Molecular genetic characterization of both components of a dedifferentiated chondrosarcoma, with implications for its histogenesis. J Pathol 1999;189:445-7.